Maspin expression and its clinical significance in non-small cell lung cancer

Annals of Surgical Oncology

Volumn 13, Issue 11, 2006, Pages 1517-1523

  Nakagawa, Masatsugu ^a   Katakura, Hiromichi ^a   Adachi, Masashi ^a   Takenaka, Kazumasa ^a   Yanagihara, Kazuhiro ^a   Otake, Yosuke ^b   Wada, Hiromi ^a   Tanaka, Fumihiro ^a,c  

^a KYOTO UNIVERSITY   (Japan)

^b Seishin Iryo Center Hospital   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Maspin; Non small cell lung cancer; p53; Prognostic factor; Tumor suppressor

Indexed keywords

MASPIN; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CONFIDENCE INTERVAL; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENCE; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADENOCARCINOMA; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MICROCIRCULATION; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SERPINS; SURVIVAL RATE;

EID: 33751020279     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9030-z     Document Type: Article

References (30)

1. Shottenfeld D. Epidemiology of Lung Cancer Philadelphia: Lippincott-Raven; 1996.
2. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22:330-53.
3. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-39.
4. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500.
5. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101:13306-11.
6. Zou Z, Anisowicz A, Hendrix MJC, et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994; 263:526-9.
7. Sheng S, Pemberton PA, Sager R. Production, purification, and characterization of recombinant maspin proteins. J Biol Chem 1994; 269:30988-93.
8. Sheng S, Carey J, Seftor EA, Dias L, Hendrix MJC, Sager R. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci USA 1996; 93:11669-74.
9. Sheng S, Truong B, Fredrickson D, Wu R, Pardee AB, Sager R. Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin. Proc Natl Acad Sci USA 1998; 95:499-504.
10. Maass N, Teffner M, Rosel F, et al. Decline in the expression of the serine protease inhibitor maspin is associated with tumour progression in ductal carcinomas of the breast. J Pathol 2001; 195:321-6.
11. Maass N, Hojo T, Ueding M, et al. Expression of the tumor suppressor gene Maspin in human pancreatic cancers. Clin Cancer Res 2001; 7:812-17.
12. Umekita Y, Ohi Y, Sagara Y, Yoshida H. Expression of maspin predicts poor prognosis in breast-cancer patients. Int J Cancer 2002; 100:452-5.
13. Bieche I, Girault I, Sabourin JC, et al. Prognostic value of maspin mRNA expression in ER alpha-positive postmenopausal breast carcinomas. Br J Cancer 2003; 88:863-70.
14. Sood AK, Fletcher MS, Gruman LM, et al. The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res 2002; 8:2924-32.
15. Mohsin SK, Zhang M, Clark GM, Allred DC. Maspin expression in invasive breast cancer: association with other prognostic factors. J Pathol 2003; 199:432-5.
16. Smith SL, Watson SG, Ratschiller D, Gugger M, Betticher DC, Heighway J. Maspin - the most commonly expressed gene of the 18q21.3 serpin cluster in lung cancer - is strongly expressed in preneoplastic bronchial lesions. Oncogene 2003; 22:8677-87.
17. Yatabe Y, Mitsudomi T, Takahashi T. Maspin expression in normal lung and non-small-cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation. Oncogene 2004; 23:4041-9.
18. Futscher BW, Oshiro MM, Wozniak RJ, et al. Role for DNA methylation in the control of cell type specific maspin expression. Nat Genet 2002; 31:175-9.
19. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111:1710-17.
20. Travis TD, Colby TV, Corrin B. Histological Classification of Lung and Pleural Tumors3 Berlin: Springer; 1999.
21. Tanaka F, Kawano Y, Li M, et al. Prognostic significance of apoptotic index in completely resected non-small-cell lung cancer. J Clin Oncol 1999; 17:2728-36.
22. Tanaka F, Otake Y, Yanagihara K, et al. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 2001; 7:3410-15.
23. Xia W, Lau YK, Hu MC, et al. High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma. Oncogene 2000; 19:2398-2403.
24. Nakashima M, Ohike N, Nagasaki K, Adachi M, Morohashi T. Prognostic significance of the maspin tumor suppressor gene in pulmonary adenocarcinoma. J Cancer Res Clin Oncol 2004; 130:475-9.
25. Hirai K, Koizumi K, Haraguchi S, et al. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer. Ann Thorac Surg 2005; 79:248-53.
26. Zou Z, Gao C, Nagaich AK, et al. p53 regulates the expression of the tumor suppressor gene maspin. J Biol Chem 2000; 275:6051-4.
27. Zhang M, Volpert O, Shi YH, Bouck N. Maspin is an angiogenesis inhibitor. Nat Med 2000; 6:196-9.
28. Machtens S, Serth J, Bokemeyer C, et al. Expression of p53 and maspin protein in primary prostate cancer: correlation with clinical features. Int J Cancer 2001; 95:337-42.
29. Umekita Y, Yoshida H. Expression of maspin is up-regulated during the progression of mammary ductal carcinoma. Histopathology 2003; 42:541-5.
30. Ohike N, Maass N, Mundhenke C, et al. Clinicopathological significance and molecular regulation of maspin expression in ductal adenocarcinoma of the pancreas. Cancer Lett 2003; 199:193-200.